NCT01650259View on ClinicalTrials.gov

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

4,876

Participants

Timeline

Start Date

July 23, 2012

Primary Completion Date

September 5, 2017

Study Completion Date

September 14, 2017

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

OAD

OAD except Trazenta tablets

DRUG

Trazenta

Linagliptin

Trial Locations (1)

Unknown

One Or Multiple Locations

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY